Immuneering (IMRX) Cash from Investing Activities (2020 - 2026)

Immuneering's Cash from Investing Activities history runs 7 years deep, the most recent figure standing at -$63.1 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 704995.3% year-over-year to -$63.1 million; the TTM figure through Mar 2026 stood at -$151.8 million (down 3115.8% YoY), while the FY2025 annual figure was -$88.7 million, down 435.69% from the prior year.
• Cash from Investing Activities was -$63.1 million for Q1 2026 at Immuneering, up from -$88.7 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $22.2 million in Q2 2022 to a low of -$88.7 million in Q4 2025.
• Historically, Cash from Investing Activities has averaged -$4.5 million across 5 years, with a median of $3.1 million in 2023.
• The sharpest annual moves came in 2022 and 2026: Cash from Investing Activities surged 111852.97% in 2022, then tumbled 704995.3% in 2026.
• A 5-year view of Cash from Investing Activities shows it stood at $8.2 million in 2022, then sank by 61.57% to $3.1 million in 2023, then jumped by 75.26% to $5.5 million in 2024, then plunged by 1715.84% to -$88.7 million in 2025, then advanced by 28.91% to -$63.1 million in 2026.
• The last three Cash from Investing Activities figures came in at -$63.1 million (Q1 2026), -$88.7 million (Q4 2025), and -$7255.0 (Q3 2025), per Business Quant data.